Related Experiment Video

Updated: Sep 29, 2026

Carotid Artery Infusions for Pharmacokinetic and Pharmacodynamic Analysis of Taxanes in Mice
08:41

Carotid Artery Infusions for Pharmacokinetic and Pharmacodynamic Analysis of Taxanes in Mice

Published on: October 27, 2014

Expression of paclitaxel-inactivating CYP3A activity in human colorectal cancer: implications for drug therapy

C Martínez1, E García-Martín, R M Pizarro

  • 1Department of Pharmacology, Medical School, University of Extremadura, Avda. de Elvas s/n, E-06071, Badajoz, Spain.

British Journal of Cancer
|September 19, 2002
PubMed

Insights

Colorectal cancer tissue contains cytochrome P450 3A (CYP3A) enzyme activity, which metabolizes anticancer drugs like paclitaxel. This CYP3A activity in tumors may affect patient response to chemotherapy.

Area of Science:

  • Pharmacology
  • Oncology
  • Biochemistry

Background:

  • Cytochrome P450 3A (CYP3A) enzymes are crucial for drug metabolism.
  • CYP3A activity is known to inactivate various anticancer drugs.
  • The role of CYP3A in colorectal cancer (CRC) and its impact on chemotherapy is not fully understood.

Purpose of the Study:

  • To investigate the presence and activity of CYP3A in human colorectal cancer tissue.
  • To determine the ability of CRC tissue to metabolize paclitaxel (a CYP3A substrate anticancer drug).
  • To assess the impact of CYP3A activity on CRC's potential to inactivate anticancer drugs.

Main Methods:

  • Analysis of CYP3A enzyme activity using nifedipine oxidation in CRC and healthy colorectal microsomes.
  • Determination of kinetic parameters (Km) for CYP3A in tumoral and healthy tissues.
  • Measurement of paclitaxel metabolism by CRC microsomes and inhibition studies using ketoconazole.

Main Results:

  • CYP3A enzyme activity was detected in both healthy and tumoral colorectal samples, exhibiting significant interindividual variability (nearly 10-fold).
  • CRC microsomes metabolized paclitaxel with a mean activity of 3.1 pmol/min/mg, primarily via CYP3A, as confirmed by ketoconazole inhibition (Ki = 31 nM).
  • The kinetic properties (Km) of tumoral CYP3A were comparable to healthy colorectal and liver enzymes.

Conclusions:

  • Colorectal cancer tissue exhibits functional CYP3A-dependent metabolic activity.
  • This metabolic capacity allows CRC cells to inactivate CYP3A substrate anticancer drugs.
  • Tumor-specific CYP3A activity may influence the efficacy and sensitivity of patients to certain chemotherapies.

More Related Videos

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers06:02

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers

Published on: February 20, 2017

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...